Merck will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). • Company’s scientific leadership […]
…First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment This data suggests the long-term positive […]
Biomedical device passes the litmus test A University of Sydney PhD researcher is developing a cancer and serious disease-detecting biomedical probe that can be made […]
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in […]
• Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions • Antigen test accurately […]
… a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis today announced that it has received notice from the US Food and […]
• Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosis • EMA approval based […]
…at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) Rapid and profound depletion of B-cells contributed to […]
• Investigational evobrutinib is the first and only Bruton’s Tyrosine Kinase inhibitor to demonstrate high and sustained efficacy through 108 weeks in clinical studies • […]
Copyright © 2023 | WordPress Theme by MH Themes
